The company was founded in 2002 with a whole-genome mapping technology and more recently moved into the microbial genetics space.
The firm said that it plans to list its stock on the Nasdaq under ticker symbol "RAIN" and added that its 2014 revenues were up 78 percent year over year to $30.6 million.
Despite an initial focus on cardiovascular disease, Miragen has moved programs in hematological cancer and fibrosis to the front of its pipeline.
The Australian company has also inked a deal to launch its proteomics-based kidney disease test in China.
The offering price and number of shares offered were above previous expectations, and Invitae's shares were up around 8 percent in Thursday morning trade.
The company said it plans to offer 3.75 million shares of its common stock and expects to fetch between $11 and $13 per share in its IPO.
The firm plans to offer 5,350,000 shares of its common stock at a price between $13 and $15 per share.
The molecular diagnostics firm anticipates fetching between $12 and $14 per share in its IPO for net proceeds of $52.2 million at the midpoint price of $13 per share.
BGI's spinoff companies, BGI Tech and BGI Dx, have merged and will go public next year.
Invitae offers NGS-based panels for a range of genetic conditions in the fields of cardiology, hereditary cancer, pediatric genetics, neurology, and hematology.
The University of California, Berkeley's Jennifer Doudna reflects at Science on the anniversary of the announcement of the birth of twin girls who underwent genome editing.
By studying its enamel proteome, researchers have found the ancient ape Gigantopithecus blacki belongs to a sister clade to that of orangutans.
Bloomberg Businessweek discusses genomics with BGI's Wang Jian.
In Science this week: researchers find transplanting the gut microbiome in mice affects physiology, and more.